Infants born to mothers with gestational diabetes treated with metformin have lower birthweight, but experience accelerated postnatal growth and have higher BMI in childhood, compared with those whose mothers were treated with insulin, suggest findings from a meta-analysis.
Findings from the SAVOR-TIMI 53 trial suggest that metformin treatment reduces cardiovascular and all-cause mortality but not nonfatal cardiovascular disease events, but a meta-analysis points to wider benefits.
Achieving very low levels of low-density lipoprotein cholesterol while on statin treatment may reduce the risk for cardiovascular disease in people with type 2 diabetes and metabolic dyslipidemia, suggest the results of a large observational study.
Findings from an observational cohort study suggest that a blood pressure target of 120/80 mmHg may be needed for effective prevention of coronary artery disease in people with type 1 diabetes.
Detailed analysis of renal outcomes in the DECLARE-TIMI 58 trial confirms that treatment with the sodium-glucose cotransporter 2 inhibitor dapagliflozin is renoprotective in patients with type 2 diabetes and preserved kidney function.
Canagliflozin reduces the risk for major cardiovascular events and kidney failure versus placebo in patients with type 2 diabetes and chronic kidney disease with and without a known history of cardiovascular disease, CREDENCE study data show.
Secondary data from the CARMELINA trial, presented at the 79th ADA Scientific Sessions in San Francisco, California, USA, confirm the positive primary cardiovascular and renal safety findings, this time in particularly high-risk patients.
The PIONEER 6 trial demonstrates the noninferior cardiovascular safety profile of oral semaglutide compared with placebo, but fails to demonstrate superiority, despite an overall positive trend and significance for cardiovascular death.
The dipeptidyl peptidase-4 inhibitor linagliptin and the sulfonylurea glimepiride have similar cardiovascular safety profiles, show the results of the CAROLINA trial.
The glucagon-like peptide-1 receptor agonist dulaglutide has demonstrated significant cardioprotection in the REWIND trial, despite the trial population being lower risk than usual for cardiovascular outcome trials.
Older people starting treatment with sodium-glucose cotransporter 2 inhibitors have a lower risk for hospitalization for heart failure than those starting glucagon-like peptide-1 receptor agonists, research shows.
Delaying diabetes onset by at least 6 years in people with impaired glucose tolerance significantly reduces their risk for cardiovascular disease and microvascular complications, show 30-year data from the Da Qing Diabetes Prevention Study.
A post-hoc analysis of the ADVANCE trial indicates that people with type 2 diabetes may benefit from additional antihypertensive medications even if their blood pressure is already below the 140/90 mmHg target.
Lifestyle interventions to delay the onset of type 2 diabetes result in marked long-term reductions in cardiovascular disease and mortality, shows the 30-year follow-up of the Da Qing Diabetes Prevention Outcome Study.
An interim analysis of EMPRISE shows reductions in heart failure risk with empagliflozin in real-world users that match those reported in the EMPA-REG OUTCOME trial.
People with type 2 diabetes are more likely to experience cardiovascular events, particularly myocardial infarction, within 3 years of starting glucose-lowering therapy if they have pre-existing ischemic heart disease, research shows.
Research using the Swedish National Diabetes Registry shows that diabetes confers a particularly high relative risk for mortality and multiple cardiovascular disease outcomes in people who are young when diagnosed.
Further analysis of the DECLARE-TIMI 58 trial shows dapagliflozin to be of particular benefit for patients who have previous myocardial infarction or heart failure with reduced ejection fraction.
A post-hoc analysis of the CANVAS trial suggests that treatment with the sodium-glucose cotransporter 2 inhibitor canagliflozin reduces the risk for heart failure events regardless of whether patients have preserved or reduced ejection fraction.
Assigning people with type 2 diabetes to 3 months of focused care with a specialist diabetes nurse after an episode of severe hypoglycemia reduces their risk for mortality over the following few years, research shows.
Sodium-glucose cotransporter-2 inhibitors have a greater effect than glucagon-like peptide-1 receptor agonists on reducing hospitalization for heart failure and kidney disease progression in patients with type 2 diabetes, according to the findings of a systematic review and meta-analysis.
A high degree of glycemic variability is associated with a significantly increased risk for midterm major cardiovascular events in patients with diabetes and acute coronary syndrome, French researchers report.
The incidence of coronary heart disease has declined in recent years but people with type 2 diabetes continue to have a significantly greater risk than those without, Scottish data show.
Long-term variation in fasting blood glucose may be associated with an increased risk for all-cause mortality, but not cardiovascular disease events, in people with no history of diabetes, US researchers report.
Individuals who maintain a blood glucose level below the diabetes threshold during middle age have a lower risk for cardiovascular disease than those who convert to diabetes during this time, observational study data show.
Over a third of time spent in hospital before the age of 40 years by patients who develop type 2 diabetes by this age is due to mental illness, report researchers.
A real-world study based on DECLARE-TIMI 58 inclusion and outcome criteria shows that dapagliflozin not only reduces cardiovascular risk among patients with type 2 diabetes, in line with the original trial results, but may also lower all-cause mortality risk.
The risk for coronary artery disease increases significantly with increasing levels of coronary artery calcification in individuals with type 1 diabetes, US researchers report.
Registry data from Denmark and Sweden uphold the cardioprotective effects of liraglutide observed in randomized trials, with the strongest effects seen in patients with established cardiovascular disease.
The LEADER investigators report that treatment with the glucagon-like peptide-1 receptor agonist liraglutide may be of particular benefit in the oldest patients with type 2 diabetes.
Patients initiating second-line therapy for type 2 diabetes have a substantial burden of both microvascular and macrovascular complications, which varies by global region, the DISCOVER study investigators report.
Sodium-glucose cotransporter 2 inhibitors reduce the risk for heart failure hospitalization and renal disease progression in patients with type 2 diabetes regardless of existing cardiovascular disease, meta-analysis data show.
The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.
Type 2 diabetes and polyvascular disease are additive risk factors for cardiovascular events in patients with acute coronary syndromes, a secondary analysis of the IMPROVE-IT trial suggests.
The protective effect of empagliflozin against cardiovascular and all-cause mortality translates into between 1.0 and 4.5 years of additional life expectancy for high-risk patients with type 2 diabetes, say the EMPA REG OUTCOME investigators.
The cardioprotective effects of liraglutide apply to patients with chronic kidney disease as well as those with established cardiovascular disease, show two post-hoc analyses of the LEADER trial.
An observational study published in JAMA demonstrates a substantial reduction in the risk for hard cardiovascular endpoints in obese patients with type 2 diabetes who have undergone bariatric surgery.
Findings from the CARMELINA trial suggest that the dipeptidyl peptidase-4 inhibitor linagliptin has a similar cardiovascular safety profile to placebo when added to standard care in high-risk type 2 diabetes patients.
Results of the Harmony Outcomes trial indicate that adding the glucagon-like peptide-1 receptor agonist albiglutide to standard care may reduce cardiovascular risk among patients with type 2 diabetes and existing cardiovascular disease.
Research suggests that giving patients with type 2 diabetes intensive blood pressure treatment as per the ACCORD BP study would be beneficial in a real-world US population.
The results of a network meta-analysis offer strong support for use of sodium-glucose cotransporter 2 inhibitors to prevent heart failure (HF) in patients with type 2 diabetes.
Findings from a phase IV trial suggest that aspirin use may reduce the risk for primary vascular events but at the cost of increased major bleeding risk in patients with diabetes, while omega-3 fatty acid supplementation does not have a cardioprotective effect.
A study of the Swedish National Diabetes Register suggests that keeping five cardiovascular risk factor variables within the target ranges could offset the excess risk for death, myocardial infarction, or stroke among patients with type 2 diabetes relative to the general population.
Patients with type 1 diabetes diagnosed before the age of 10 years have a higher risk for cardiovascular complications and a shorter life expectancy than those who develop the disease at an older age, study results published in The Lancet suggest.
Patients who are not diligent about taking their antidiabetic medications during the first year after type 2 diabetes diagnosis are at increased risk for cardiovascular events and death over the subsequent years, research shows.
The best markers for prediction of cardiovascular events in patients with type 2 diabetes may vary according to whether or not the patient already has cardiovascular disease, study findings indicate.
Research shows that starting second-line sulfonylurea treatment is associated with an increased risk for cardiovascular and hypoglycemic events among patients with type 2 diabetes in clinical practice, although the risk is less if they continue using metformin rather than switching completely.
An evaluation of several cardiovascular disease risk scores has highlighted poor performance of these tools among individuals with newly diagnosed type 2 diabetes.
A secondary analysis of the CANVAS trial supports the beneficial cardiovascular and renal effects of sodium-glucose cotransporter 2 inhibition down to a low level of kidney function.
The likelihood of dying during or soon after heart failure hospitalization is higher among patients with type 1 than type 2 diabetes, report researchers.
Analysis of the Health and Retirement Study indicates that the adverse effects of earlier age of type 2 diabetes onset are also evident in an older population.
A 6-year diet and exercise intervention significantly reduces the long-term risk for cardiovascular disease in Chinese adults with impaired glucose tolerance, research suggests.
When levels of N-terminal pro B-type natriuretic peptide are persistently high or rising, patients with type 2 diabetes are at increased risk for being hospitalized with heart failure or dying of cardiovascular causes, research shows.
Research from the IPD-Work consortium indicates that the mortality risk associated with work stress is largely confined to men with cardiometabolic disease.
Mortality rates in people with diabetes are falling faster than in those without diabetes, with the greatest decline seen in deaths from vascular causes, US study data show.
Data from primary care indicate that more successful control of vascular risk factors in patients with type 2 diabetes and chronic kidney disease is associated with reduced risk for cardiovascular disease and mortality.
An individual patient data meta-analysis confirms that diabetes increases the likelihood for people dying of atherosclerotic disease, with women the worst affected.
A network meta-analysis published in JAMA offers indirect comparisons of the survival benefits associated with use of the most recent antidiabetic agents.
Adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin and sulfonylurea treatment may improve glycemic control in patients with type 2 diabetes and high cardiovascular risk, a post-hoc analysis of the EXAMINE trial suggests.
A drive to improve cardiovascular risk factors at the level of the healthcare system results in reduced vascular risk in patients with diabetes, research shows.
Deaths from vascular, renal, and infectious causes substantially increase with increasing diabetes duration and worsening glycemic control, results of the Mexico City Prospective Study show.
UK Biobank data add to the evidence challenging the existence of the obesity paradox by showing that cardiovascular disease risk increases linearly with increasing adiposity in middle-aged men and women.
Study results presented at the 2018 Diabetes UK Professional Conference in London confirm that people who are diagnosed with type 2 diabetes at a younger age have an increased mortality risk.
The latest analysis from the CVD-REAL 2 investigators shows reduced cardiovascular risk associated with sodium-glucose cotransporter 2 inhibitor use among diabetes patients from Asia Pacific, North America, and the Middle East.
Results of a US database study suggest that the sodium-glucose co-transporter-2 inhibitor canagliflozin is associated with a lower risk for heart failure hospitalization compared with three other classes of antidiabetes agent.
An analysis of TECOS data highlights a bidirectional relationship between severe hypoglycemic events and adverse cardiovascular outcomes in patients with type 2 diabetes.
A mediation analysis indicates that empagliflozin may provide cardioprotection largely through its ability to reduce plasma volume, with traditional cardiovascular risk markers playing little or no role.
An increased urinary albumin to creatinine ratio is significantly and independently associated with an increased risk for cardiovascular outcomes in patients with type 2 diabetes, an analysis of SAVOR-TIMI 53 data shows.
Intensive blood pressure management benefits patients whether or not they have diabetes and regardless of their baseline level of cardiovascular disease risk, shows a pooled analysis of the SPRINT and ACCORD-BP trials.
A meta-analysis published in The Lancet Diabetes & Endocrinology is suggestive of a class cardioprotective effect for the glucagon-like peptide-1 receptor agonists.
A novel approach of using children’s BMI as a surrogate for their parents’ weight confirms that overweight and obesity increase people’s mortality risk.
Intensive treatment of type 1 diabetes appears to reduce the risk for cardiovascular disease events even in those who gain excessive weight, but improved management of cardiovascular risk factors and revascularization may be needed.
Further analysis of the CANVAS trial suggests that the benefits of canagliflozin treatment are broadly consistent in type 2 diabetes patients with and without pre-existing cardiovascular disease,
Cardiovascular complications, and heart failure in particular, are strongly associated with poor survival in elderly patients with type 2 diabetes, French observational study data show.
Results of AdDIT show that treatment with an ACE inhibitor, a statin, or both does not protect against the increased albumin excretion that frequently occurs in patients with type 1 diabetes during adolescence.
Metformin status at the time of initial dipeptidyl peptidase 4 inhibitor use may influence the effect these agents have on cardiovascular outcomes, be it positive or negative, suggest results of a hypothesis-generating meta-analysis.
Results of the VIVIDD trial indicate that it is unclear whether treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin has a beneficial effect on cardiac outcomes among patients with heart failure and type 2 diabetes.
Results of a study published in JACC: Heart Failure suggest that glycemic control and drug treatment have complex associations with adverse outcomes among patients with heart failure and type 2 diabetes.
Women with a history of gestational diabetes have a significantly increased risk for cardiovascular disease, which may be modified by healthy lifestyle factors, prospective study data show.
Sudden death is the most common cause of cardiovascular death among patients with type 2 diabetes and atherosclerotic cardiovascular disease, an analysis of TECOS data shows.
A post-hoc analysis of the ACCORD-BP trial suggests that the presence of additional cardiovascular risk factors may be key for patients with type 2 diabetes to derive benefit from intensive blood pressure control.
Patients with type 2 diabetes can be divided into three groups with distinct clinical profiles based on echocardiographic measures, researchers report.
The PURE study shows that the cardiovascular disease and mortality risk reductions attainable with regular physical activity apply regardless of whether people live in countries with high, middle, or low income.
Study results presented at the EASD annual meeting in Lisbon, Portugal, demonstrated the potential of several novel therapies for the treatment of obesity-related metabolic dysfunction and type 2 diabetes.
Results presented during an EASD annual meeting session on hypoglycemia covered risk factors and consequences, and looked at the optimal insulin management approach for diabetes patients wishing to observe Ramadan.
Researchers presented the results of several studies investigating the risks associated with nonalcoholic fatty liver disease and potential treatment strategies at the EASD annual meeting in Lisbon, Portugal.
Asking two simple questions about the vitality and energy of patients with type 2 diabetes may help healthcare providers to predict their risk for major adverse cardiovascular events.
Analysis of data from the EMPA-REG OUTCOME trial suggests that the beneficial effects of empagliflozin on mortality risk in patients with type 2 diabetes and established cardiovascular disease occur independently of its influence on traditional cardiovascular risk factors.
The results of the Exenatide Study of Cardiovascular Event Lowering study show that the glucagon-like peptide-1 receptor agonist has a neutral cardiovascular effect, the investigators have reported at the EASD annual meeting, in Lisbon, Portugal.
The CVD-REAL investigators have presented further results demonstrating the effects of sodium-glucose co-transporter 2 inhibitors on cardiovascular outcomes in real-world clinical practice.
The TOCSA.IT investigators have found no differences in cardiovascular disease outcomes between patients with type 2 diabetes taking pioglitazone versus sulfonylurea over nearly 5 years.
The α-glucosidase inhibitor acarbose does not reduce cardiovascular risk but could decrease the risk for developing type 2 diabetes among patients with coronary heart disease and impaired glucose tolerance, results of the phase IV placebo-controlled ACE trial suggest.